Global Cybersecurity Market To Reach $1 Trillion Annually By 2031
'Global spending on cybersecurity products and services is expected to reach $454 billion annually (USD) in 2025, up from $260 billion in 2021.'— Cybersecurity Ventures
SAN FRANCISCO, CA, UNITED STATES, April 28, 2025 / EINPresswire.com / -- The imperative to protect increasingly digitized businesses, governments, schools, Internet of Things (IoT) devices, and consumers from cybercrime will propel global spending (1) on cybersecurity products and services to $1 trillion (USD) annually by 2031, according to the 'Cybersecurity Market Report' due out from Cybersecurity Ventures and Evolution Equity Partners on Jun. 16, 2025.
Global spending on cybersecurity products and services is expected to reach $454 billion annually (USD) in 2025, up from $260 billion in 2021.
'In advance of the report, we are releasing our cybersecurity market prediction today at the RSA Conference 2025 in San Francisco' says Steve Morgan, founder of Cybersecurity Ventures. For 32 years, the RSA Conference has been a driving force behind the world's cybersecurity community.
AI is expanding a $2 trillion total addressable market or TAM (2) for cybersecurity providers, according to a 2024/2025 study by McKinsey, a global management consulting firm and trusted advisor to the world's leading businesses, governments, and institutions.
'One of the areas that is extremely compelling is the opportunity to build a security layer around agentic AI,' says Richard Seewald, founder and Managing Partner at Evolution Equity Partners. 'If you think about the volume of agents that will be put into the market, the opportunity to create cybersecurity companies that defend and protect that layer are significant.'
McKinsey's study is particularly relevant to the CISOs and vendors, the cybersecurity buyers and sellers, who made a pilgrimage to this year's RSA Conference.
'Based on the organizations we have served, cyber budgets are still under tremendous pressure to reduce cost when, in reality, they are often under-budgeting when framed in terms of the organization's risk profile,' says Justin Greis, Partner and North American Cybersecurity Practice Leader at McKinsey.
'More often than not, when we are engaged to analyze and possibly reduce cybersecurity costs, we typically end up increasing the cyber budget because the cyber risks uncovered exceed management's and the board's risk appetite,' adds Greis. 'More and more CISOs are requesting and reporting their budgets, not just in dollars and cents, but framed in terms of risk to critical business processes, products, services, or strategic goals/objectives.'
Today, nearly 15 percent of (corporate) cybersecurity spending comes from outside the chief information security office (CISO), and non-CISO cyber spending is expected to grow at a 24 percent CAGR over the next three years, according to the McKinsey study, which goes on to state that this has changed from a decade ago, when almost all cybersecurity spending came from the CISO organization.
Going forward, providers will need to increasingly cater to non-CISO customers, the McKinsey study posits, with most non-CISO cyber spending coming from buying centers responsible for cloud, product, network, and audit and compliance.
Despite its current market size, cybersecurity has a lot of headroom to grow.
'We are still in the early innings of a secular trend in the cybersecurity space that involves increased spend by large enterprises, smaller businesses and consumers alike, a rapidly expanding attack surface, market consolidation and demand for next generation products and services that makes this a very compelling segment for investment,' says Dennis Smith, Founder and Managing Partner at Evolution Equity Partners.
(1) Spending is actual dollars spent, or expected to be spent. The spending prediction figures from Cybersecurity Ventures includes all countries globally, B2B and B2C, plus a portion of any markets that are converged with cybersecurity such as physical security and surveillance, as well as automotive security, medical device security, military cyber defense technology, and others. It also counts in cyberinsurance policies.
(2) TAM is the total revenue opportunity available to a product or service if 100 percent market share is achieved. TAM does not represent actual dollars spent, or expected to be spent. The TAM figures from McKinsey are global and primarily focused on B2B, but not B2C or other markets converged with cybersecurity such as physical security and surveillance, automotive security, and others.
ABOUT
Cybersecurity Ventures is a leading cybersecurity market watcher and the publisher of Cybercrime Magazine, Page ONE for the global cyber economy, and a trusted source for cybersecurity facts, figures, and statistics.
Evolution Equity Partners is an international venture capital investor led by technology entrepreneurs who have built software companies around the world and who leverage tremendous operating, technical, product development and go-to-market expertise to help entrepreneurs win.
Malcomb Farber
Cybersecurity Ventures
+1 631-680-8660
email us here
Visit us on social media:
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
29 minutes ago
- Associated Press
The $400 Billion Blind Spot: Why Autonomous Endpoint Management is the Only Way Enterprises Will Survive the Apocalypse
BOSTON, MA / ACCESS Newswire / August 15, 2025 / 'Every enterprise leader claims to have a digital transformation strategy. Yet, behind the boardroom bravado, a silent crisis is draining billions from the world's largest companies. The culprit? A tidal wave of devices-laptops, tablets, phones, IoT sensors-sprawling across continents, each one a potential point of failure. According to IoT Analytics, by 2030, the number of connected devices will soar from 16.6 billion to 40 billion, turning endpoint management into a logistical nightmare (IoT Analytics, 2023). The cost of this chaos is staggering. Global downtime now burns through $400 billion a year, with every minute offline costing $9,000 (Splunk, 2023). Yet most organizations still rely on slow, reactive, and generic endpoint management tools-paying an invisible tax of over $50 billion in operations and $275 billion in lost productivity every year. Shirish Nimgaonkar, Founder and CEO of eBlissAI, doesn't mince words: 'Enterprises are fighting 21st-century endpoint complexity with 20th-century tools. The cost isn't just financial-it's existential. If you can't manage your endpoints, you can't scale your AI. And if you can't scale your AI, you're already behind.' The Boardroom Power Shift CIOs and CTOs have never been more central to the enterprise agenda. According to the Wall Street Journal, sixty-three percent now report directly to the CEO-a leap driven by the promise of AI and the demand for business outcomes (WSJ, 2024). But with that influence comes a new kind of pressure: deliver measurable ROI, or risk being replaced. Boards are no longer satisfied with pilots and proofs of concept. They want AI that moves the needle-now. The AI Adoption Paradox The AI gold rush is in full swing. McKinsey reports that seventy-eight percent of companies have adopted AI in at least one function, but only 1% have managed to scale it across the enterprise to generate tangible ROI (McKinsey, 2023). Most see cost savings under 10% and revenue increase bumps below 5% (WSJ, 2023). The reason? AI pilots are easy. Enterprise-wide impact is hard. The focus must shift to repeatable, scalable outcomes. The Endpoint Management Revolution The answer lies in autonomous endpoint management. Instead of relying on armies of IT staff to manually patch, update, and secure devices, agentic AI can now manage endpoints at scale-predicting disruptions before they happen, automating issue resolution, and continuously optimizing performance. 'AI for AI's sake is meaningless. What enterprises need is AI that works quietly in the background, delivering measurable productivity gains and reducing costs at scale. That's the promise eBlissAI fulfills,' says Nimgaonkar. Early adopters have seen dramatic results: up to 90% reduction in system downtime, 95% improvement in threat detection, and a 70% drop in operational costs (IT News Online, 2024). According to IT News Online, eBlissAI delivers ROI up to 45x higher than traditional solutions. The New Mandate for CIOs The message is clear: enterprises that fail to adapt will be left behind. 'eBlissAI isn't just another platform-it's the CIO's co-pilot in the age of AI. We deliver a bold promise: tangible, differentiated business outcomes in a defined time period,' Nimgaonkar asserts. The age of autonomous endpoint management has arrived. The only question is: will your enterprise survive the coming apocalypse-or become another casualty of the $400 billion blind spot? Sources IoT Analytics. (2023). 'The Future of Connected Devices.' Splunk. (2023). 'The Cost of Downtime.' Wall Street Journal. (2024). 'CIOs and CTOs Now Report Directly to the CEO.' McKinsey. (2023). 'The State of AI Adoption.' IT News Online. (2024). 'eBlissAI Delivers 45x ROI Over Traditional Solutions.' Contact Information Jack Smith Media Coordinator +1-442-220-3131 SOURCE: eBlissAI press release
Yahoo
an hour ago
- Yahoo
Fixed Price Contracts Dominate, Offering Stability in Catering Agreements
Key market opportunities in the global contract catering sector include capitalizing on evolving consumer preferences for healthier, diverse options, leveraging the outsourcing trend for operational efficiency, emphasizing sustainability, and integrating technological advancements. Europe dominates, driven by workplace well-being and stringent regulations. Contract Catering Market Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Contract Catering Market Report by Contract Type, and Region 2025-2033" has been added to offering. The global contract catering market is poised for substantial growth, with its size projected to rise from USD 269.0 billion in 2024 to USD 392.1 billion by 2033, at a CAGR of 4.3% from 2025 to 2033. Key factors fueling this growth include a shift towards healthier food preferences, increased outsourcing of food services for operational efficiency, emphasis on sustainability, technological advancements, and stringent regulatory environments. Contract catering, defined by its contractual agreements, offers diverse food services to various sectors including corporate offices, educational institutions, and healthcare facilities. These arrangements enable seamless integration into client operations, offering benefits such as economies of scale, varied menu options, and adherence to quality standards. Service types range from onsite cafeterias to specialized event catering. Evolving Consumer Preferences: The increasing demand for healthier and diverse food options has driven catering companies to expand their offerings. Consumers now require plant-based, organic, and allergen-free choices, alongside transparency in sourcing. This trend enhances customer experience and provides a competitive advantage to catering companies that can adapt to these demands. Outsourcing for Operational Efficiency: Outsourcing food services has emerged as a major market driver, allowing businesses to streamline operations and cut costs while ensuring high-quality food services. This is particularly preferred in sectors like healthcare and education aiming for nutritious meal delivery alongside resource optimization. Catering companies demonstrating operational expertise stand to benefit significantly from this trend. Sustainability and Responsible Sourcing: The focus on environmentally friendly practices and ethical sourcing is transforming the market. Catering providers are expected to source locally, minimize waste, and use eco-friendly packaging. This commitment to sustainability not only attracts eco-conscious clients but also enhances the company's reputation and compliance with broad sustainability goals. The market segmentation includes contract types (fixed price, cost plus), mode of contract (outsourced, self-operated), and end user segments (business and industry, education, healthcare, and others). Fixed price contracts and outsourced modes dominate the market due to their predictability, trust-building capabilities, and operational efficiencies. Business and industry sectors represent the largest market share, driven by the need for efficient food solutions in corporate environments and the growing importance of employee well-being and engagement. Regionally, Europe leads the contract catering market due to its rich culinary heritage, focus on employee satisfaction, and stringent food safety regulations. The emphasis on sustainability further drives this regional dominance. The competitive landscape is vibrant, with major players like ABM Catering Solutions, Aramark, and Sodexo leading the charge. Companies are leveraging diverse menus, innovative technology, and a commitment to sustainability to stay competitive. Key Attributes: Report Attribute Details No. of Pages 140 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $269 Billion Forecasted Market Value (USD) by 2033 $392.1 Billion Compound Annual Growth Rate 4.3% Regions Covered Global Companies Featured ABM Catering Solutions Amadeus Aramark Atalian Servest Barlett Mitchell Blue Apple Catering Camst Group Caterleisure Ltd. CH&CO Catering Compass Group PLC Dine Contract Catering Elior Group Fazer Food Services Interserve OCS Group Ltd. Sodexo For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Contract Catering Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Oligonucleotide CDMO Market to Soar USD 18.37 Billion at 21.83% Strong CAGR by 2034
The global oligonucleotide CDMO market is valued at USD 3.11 billion in 2025 and is projected to reach approximately USD 18.37 billion by 2034, expanding at a CAGR of 21.83% over the forecast period. Ottawa, Aug. 08, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister company of Precedence Research, the global oligonucleotide CDMO market size to grow from USD 2.55 billion in 2024 and is expected to expand USD 18.37 billion by 2034. The growth of the market is driven by the increased demand for specialized techniques, which are technologically advanced due to the growing prevalence of chronic diseases in the region. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the oligonucleotide CDMO market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. By service, the contract manufacturing segment led the market in 2024. By service, the contract development segment is estimated to achieve significant growth during the forecast period. By type, the ASO segment held a significant share of the market in 2024. By type, the siRNA segment is expected to grow significantly during the forecast period. By application, the therapeutic segment held the largest share of the oligonucleotide CDMO market in 2024. By application, the research segment is anticipated to grow at a significant rate during the forecast period. By end-use, the pharma segment held a major share of the market in 2024. By end-use, the biotech segment is anticipated to achieve a significant share of the market during the forecast period. Market Overview & Potential An oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in offering comprehensive services for developing and manufacturing short oligonucleotides, which are synthetic nucleic acid sequences used in various biotech and pharmaceutical applications. These organizations provide expertise in custom synthesis, process development, scale-up, and GMP manufacturing of oligonucleotides. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Growth Potential Responsible for The Growth of The Oligonucleotide CDMO Market? The growth of the market is driven by the growing demand for personalized medicines and RNA therapeutics, which demand specialized manufacturing capabilities, which fuels the growth of the market. The increasing prevalence of chronic diseases, especially cancer and cardiovascular diseases, with advancements in oligonucleotide manufacturing to improve synthesis technologies with automated techniques, drives the growth of the market. Other key growth drivers are government support and funding, increased investment in biotechnology, globalization, and increased collaboration boost the growth of the market. What Are the Emerging Trends in the Oligonucleotide CDMO Market? Growing Demand for Oligo-based Therapies: Oligonucleotides, including antisense oligonucleotides and small interfering RNAs, are increasingly recognized as therapeutic agents because of their targeted action and specificity. Focus on Precision Medicine: The shift toward personalized treatments designed for individual patients is boosting the need for specialized oligonucleotide therapies. Increased FDA Approvals: The rising number of FDA approvals for oligonucleotide-based drugs, such as Qalsody for ALS, further fuels market growth and stimulates innovation. Cost Efficiency and Expertise: Outsourcing to CDMOs enables companies to utilize specialized knowledge and potentially lower costs associated with in-house manufacturing, particularly for complex processes. What Are the Major Challenges Facing the Oligonucleotide CDMO Market? The market encounters several notable challenges, mainly due to manufacturing complexity, regulatory obstacles, and the need for advanced expertise and infrastructure. Scaling from research to commercial volumes, achieving high purity, and ensuring delivery efficiency to target sites are significant hurdles. Evolving regulatory requirements and the need for specialized skills in oligonucleotide synthesis, purification, and conjugation also contribute to the difficulty. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Insights Why Did North America Lead the Oligonucleotide CDMO Market in 2024? North America held a dominant position in 2024 due to its well-established research facilities, substantial R&D investments in peptide and oligonucleotide therapies, and a higher prevalence of chronic diseases. The demand for biopharmaceuticals like oligonucleotides and peptides supports this growth. North American CDMOs are well-equipped to meet this demand by providing specialized development and manufacturing services for these complex compounds. The market expansion is driven by ongoing investments from pharmaceutical and biotech firms into R&D, often through partnerships with CDMOs to access advanced infrastructure and expertise. High R&D investment, advanced biotech infrastructure, rising chronic disease prevalence, and strong pharmaceutical industry demand drive U.S. oligonucleotide CDMO growth. Regulatory clarity from the FDA, increasing personalized medicine focus, and government support for genomics research further enhance market expansion, fostering innovation and strategic collaborations with contract manufacturers. Government incentives for biotechnology, a skilled scientific workforce, and growing demand for precision medicine propel Canada's oligonucleotide CDMO sector. Strong academic-industry partnerships, supportive regulatory frameworks, and increasing investments from global pharma companies in Canadian CDMO facilities promote innovation, clinical trials, and manufacturing scalability within the country. Why Is Asia Pacific Projected to Show Rapid Growth in the Oligonucleotide CDMO Market? Asia Pacific is anticipated to be the fastest-growing region for oligonucleotide CDMOs during the forecast period. Countries like China, Japan, India, and South Korea are leading due to their large populations, focus on biopharmaceutical innovation, and strong healthcare investments. The region's market share has notably increased over recent years, supported by economic growth and rising prosperity, making it attractive for pharmaceutical outsourcing. This growth is further fueled by increased R&D funding and improvements in healthcare infrastructure. Rapid biotechnology expansion, government funding, and a large patient population fuel oligonucleotide CDMO growth in China. Domestic pharma companies increasingly outsource production, while favorable policies, infrastructure development, and cost advantages attract global partnerships. China's focus on RNA therapeutics and local innovation also accelerates CDMO sector maturation and competitiveness. Low manufacturing costs, a strong generic pharmaceutical base, and a growing talent pool drive India's oligonucleotide CDMO growth. Government initiatives supporting biotech innovation, rising contract research demand, and increased interest from Western firms in Indian CDMOs contribute. The expanding clinical trial ecosystem further enhances market attractiveness and outsourcing potential. Become a valued research partner with us - Segmental Insights Which Service Segment Dominated the Oligonucleotide CDMO Market in 2024? The contract manufacturing segment led the market in 2024, driven by the rising need for wide-scale, cGMP-compliant oligonucleotide APIs for clinical and commercial use. To meet the growing demand for ASOs, siRNAs, and mRNA-based therapies, CDMOs equipped with advanced solid-phase synthesis, automated fill-finish systems, and high-throughput purification are vital. This leadership is reinforced by pharmaceutical companies' reliance on CDMOs for high-purity, scalable, and globally compatible manufacturing solutions, driven by strict regulations and expansion challenges. This led to a growing and expanding influence on market growth. The contract development segment is estimated to achieve significant growth during the forecast period. Encompassing services like preclinical development, formulation, process development, and analytical techniques. These services are crucial for optimizing production processes and ensuring the safety and quality of oligonucleotides and peptides. R&D in oligonucleotide therapies is a key investment focus for pharma and biotech companies. Partnering with CDMOs allows these companies to reduce costs and accelerate product development, focusing on their core competencies. How did ASO Segment Dominated the Oligonucleotide CDMO Market in 2024? The ASO segment held a significant share of the market in 2024. Over the decades, the biotech and pharma industries have developed innovative approaches to target disease-related proteins, demanding innovation and development of new technologies and forms of products, which increases the demand for the market. RNA therapeutics, especially antisense oligonucleotides, have made significant progress in the market. Several ASO-based drugs are already FDA-approved, with many more under clinical testing. These factors support the growth and expansion of the market. The siRNA segment is expected to grow significantly during the forecast period. SiRNA technologies offer speed and specificity, helping to overcome preclinical drug development hurdles, which fuels the demand for the market. They currently assist in identifying the most promising pharmacological targets for specific diseases and are being explored for new, potent applications in drug candidate prioritization. These applications and benefits offered by the segment promote the growth and expansion of the market. Which Application Segment Dominated the Oligonucleotide CDMO Market in 2024? The therapeutic segment held the largest share of the market in 2024. Approaches have been developed to enhance the pharmacokinetics and pharmacodynamics of oligonucleotides. Historically targeted at rare diseases and niche markets, oligonucleotides now benefit large patient groups. The field is rapidly expanding despite fluctuations, with 44 companies having compounds in late-stage clinical trials or on the market. Major players include Johnson & Johnson, Roche, Novartis, and AstraZeneca, alongside specialized biotech firms like Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Concurrently, there has been notable activity in oligonucleotide patents and applications influencing the growth. The research segment is anticipated to grow at a significant rate in the oligonucleotide CDMO market during the forecast period, with contributions from research institutions impacting early-stage research, innovative technologies, and scientific breakthroughs. These institutions are vital in identifying therapeutic potentials, fostering partnerships with CDMOs and pharma companies, and influencing market dynamics. Advances in distribution, analytics, and synthesis are driving market expansion, and published research influences development and manufacturing strategies. How did the pharma Segment dominate the Oligonucleotide CDMO Market In 2024? The pharma segment accounted for a major market share in 2024. The advent of oligonucleotide therapies has revolutionized medicine, with several approved in the US and EU. These include a mix of single and double-stranded polydeoxyribonucleotides, six siRNAs, twelve ASOs, and one aptamer. The growing pharma sector and the application of oligonucleotides increase the demand for manufacturing and production, which contributes to the growth and expansion of the market. The biotech segment is also expected to claim a significant market share, enabled by protein-DNA functionalization through covalent bonding. This technology facilitates the creation of therapeutic molecules with potential applications for diseases like AIDS and cancer. The ongoing research and development in the biotech sector further propels the growth and expansion of the market. Recent Developments in the Oligonucleotide CDMO Market In April 2025, Sumitomo Chemical announced the launch of its new company, Sumitomo Chemical Advanced Medical Solutions America LLC, in Massachusetts to serve as its Oligonucleotide CDMO2 business. The company will provide gRNA samples to customers by August 2025. In July 2024, Agilent Technologies announced a strategic agreement to acquire BioVectra, a specialized CDMO, for $925 million. The acquisition was made to build Agilent Technologies' CDMO specialization in oligonucleotides and CRISPR therapeutics, expanding its portfolio of services and bringing world-class capabilities to support gene editing. Browse More Insights of Towards Healthcare: The global life science CDMO market is witnessing rapid expansion, with revenues projected to reach several hundred million dollars by the end of the forecast period (2025–2034). The veterinary CRO and CDMO market was valued at USD 7.17 billion in 2024, is expected to reach USD 7.77 billion in 2025, and is projected to climb to approximately USD 16.13 billion by 2034, growing at a CAGR of 8.43% during 2025–2034. The advanced therapy medicinal products (ATMP) CDMO market stood at USD 6.73 billion in 2024, increased to USD 7.99 billion in 2025, and is forecast to surge to USD 37.27 billion by 2034, registering a CAGR of 18.82% from 2025 to 2034. The investigational new drug CDMO market was valued at USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is anticipated to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% between 2025 and 2034. The mRNA therapeutics CDMO market was worth USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to grow to USD 13.63 billion by 2034, recording a CAGR of 11.37% during 2025–2034. The CDMO services for pharma and biotech market is experiencing substantial growth from 2024 to 2034, fueled by the increasing outsourcing trend among pharmaceutical and biotechnology companies. The CDMO aseptic filling solutions market is set for strong growth throughout the forecast period, driven by rising demand for sterile manufacturing capabilities and specialized injectable therapies. The active pharmaceutical ingredients (API) CDMO market was valued at USD 127.45 billion in 2024, increased to USD 136.92 billion in 2025, and is estimated to reach USD 260.98 billion by 2034, growing at a CAGR of 7.43% from 2025 to 2034. The small molecule CDMO market stood at USD 72.81 billion in 2024, rose to USD 78.01 billion in 2025, and is forecast to hit USD 145.12 billion by 2034, expanding at a CAGR of 7.14% during 2025–2034. The topical drugs CDMO market was worth USD 46.32 billion in 2024, increased to USD 51.62 billion in 2025, and is expected to reach USD 136.71 billion by 2034, registering a CAGR of 11.43% between 2025 and 2034. Top Companies and Their Contributions to the Market Contributions & Offerings to the Oligonucleotide CDMO Market Bachem A global leader in peptide and oligonucleotide synthesis, Bachem offers full CDMO services including development, GMP manufacturing, and analytics. Thermo Fisher Scientific Inc. Provides end-to-end oligonucleotide services, from preclinical to commercial scale, leveraging advanced technologies and global infrastructure. Agilent Technologies, Inc. Offers custom oligo synthesis and quality control platforms, supporting therapeutic development with scalable manufacturing capabilities. EUROAPI Delivers active pharmaceutical ingredient (API) production, including oligonucleotides, with a focus on quality, sustainability, and innovation. ST Pharm Specializes in large-scale GMP oligonucleotide manufacturing, supplying APIs globally with expertise in modified nucleic acids and cGMP compliance. Kaneka Eurogentec S.A. Provides custom manufacturing of therapeutic oligonucleotides, with cGMP-grade synthesis, formulation, and analytical support. Ajinomoto Co., Inc. Leverages proprietary biotechnologies for oligonucleotide production, offering scale-up and process development through its CDMO division. Aurigene Pharmaceutical Offers integrated CDMO services including oligonucleotide synthesis, analytical development, and GMP manufacturing for global biopharma clients. Syngene International Provides end-to-end oligo development and manufacturing, supporting early-stage to commercial scale with regulatory expertise. PolyPeptide Group Recently expanded into oligonucleotide CDMO services, combining peptide and oligo synthesis capabilities with advanced regulatory compliance. Key Players in Oligonucleotide CDMO Market Bachem Thermo Fisher Scientific Inc. Agilent Technologies, Inc. EUROAPI ST Pharm Kaneka Eurogentec S.A. Ajinomoto Co., Inc. Aurigene Pharmaceutical Services Ltd. Syngene International Limited PolyPeptide Group WuXi AppTec Eurofins Scientific GenScript Lonza Danaher Corporation Segments Covered in The Report By Service Contract Manufacturing Clinical Commercial Contract Development By Type ASO siRNA CPG Oligos gRNA By Application Therapeutic Research Diagnostics By End-User Pharma Biotech By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data